Navigation Links
ADVENTRX Announces Establishment of Regulatory Advisory Board
Date:4/9/2012

ot limited to, statements regarding the RAB's potential impact on the success of ADVENTRX's drug development programs, ADVENTRX's development plans for ANX-188, including the nature and timing of future clinical studies, and ANX-188's potential as an effective treatment for sickle cell disease patients. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but are not limited to:  the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, partner its product candidates at inopportune times or pursue less expensive but higher-risk development paths if it is unable to raise sufficient additional capital as needed; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for delays in the commencement or completion of its planned clinical studies including as a result of difficulties or delays in completing manufacturing process development activities and manufacturing clinical trial material; the risk of suspension or termination of a clinical study including due to lack of adequate funding; the risk that planned clinical studies of ADVENTRX's product candidates, including ANX-188, are not successful and, even if they are successful, that the FDA could determine they are not sufficient to support an NDAs for the product candidate; the risk that the FDA does not grant market approval of ADVENTRX's product candidates, including ANX-188, on a timely basis, or at all; ADVENTRX's reliance on third parties to assist in the conduct of important aspects of its product candidates' development programs, including the manufacture of clinical trial material, the conduct of clinical studies and regulatory submissions related to product approval, and that such third parties may fail to perform as
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ADVENTRX Announces Appointment of Senior Vice President, Commercial
2. ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
3. ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
4. ADVENTRX Pharmaceuticals Announces Financing
5. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
6. ADVENTRX Pharmaceuticals Announces Closing of Financing
7. ADVENTRX Pharmaceuticals Announces Financing
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
9. ADVENTRX Announces Further Cost-Cutting Measures
10. ADVENTRX Provides Update on Strategic Transaction Process
11. ADVENTRX Announces Further Cost-Cutting Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 BerGenBio ... today announces that an abstract on the latest data ... of the Axl receptor tyrosine kinase, and BGB10C9, an ... has been published in conjunction with the 2015 American ... Chicago , May 29 - June 2, ...
(Date:5/29/2015)... , May 29, 2015 ... as p ersonalized   treatments enter arena, ... Despite generic erosion facing several of the ... Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market ... by the end of the decade.   ...
(Date:5/29/2015)... 2015 When a leading manufacturer ... request to design an industrial oven ... medications being produced using a 3D-printing process, Gruenberg ... robotic gantry, heat-saving windows, and internal actuators and ... 3D-printed pills to exact specifications. , To ensure ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report deals with ... classical use mainly to describe the chromosome structure ... age of molecular biology, it is also referred ...
Breaking Biology Technology:BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3
... Technology Can Solve Pressing Food, Fuel Problems of ... ON, Dec. 3 /PRNewswire/ - Dr. David Dennis, FRSC, CEO of ... at a side event at the United Nations Climate Change Conference ... solved global problems in the 20th Century and the role it ...
... DEERFIELD, Ill., Dec. 3 Today, the International Society,for ... stem cell researchers, released new guidelines for the responsible,development ... A,Commentary article that summarizes the Guidelines for the ... Press in the December issue of Cell,Stem Cell, the ...
... VIENNA, Va., Dec. 3 In response to numerous,shareholder ... it has added updated pictures of it new manufacturing ... CEL-SCI,s homepage,( http://www.cel-sci.com ) by clicking on the link ... , CEL-SCI is ...
Cached Biology Technology:Leading Canadian Scientist to speak at UN Climate Change Conference 2The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 2The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 3The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 4
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... - Coding variants in immune disease-related genes play only ... psoriasis, according to a new study led by Anhui ... by their investigation on the contribution of functional coding ... a large-scale investigation, researchers only discovered two independent low-frequency ...
... Baltimore, MD November 9, 2013 New research ... Americans with chronic kidney disease contribute to a more ... The research, led by investigators from the University of ... help explain, in part, why even after accounting for ...
... other devices that can change shape or move with ... may be possible through research led by the University ... when triggered by light, thereby converting light energy into ... machine components such as switches and power sources. ...
Cached Biology News:The contribution of coding variants to psoriasis much smaller than thought 2Genetic variation increases risk of kidney disease progression in African-Americans 2Genetic variation increases risk of kidney disease progression in African-Americans 3Genetic variation increases risk of kidney disease progression in African-Americans 4Snap to attention: Polymers that react and move to light 2
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
DONOR BOVINE SERUM AND PLASMA...
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: